PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo
PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...
Precision Medicine Online8d
PDS Biotech Cleared to Begin Trial of Immunotherapy Combo in MUC1-Positive Colorectal Cancer
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.
GlobalData on MSN2mon
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Hosted on MSN6mon
New Antibody Detection Technique Offers Breakthrough in Early Pancreatic Cancer Diagnosis
The glycosylation pattern of TA-MUC1 in tumors differs from its normal form, making it a key indicator of the disease. Related News | How Does AI Help In Early Detection and Treatment Of Cancer?
Morningstar9d
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
“MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an ...
manilatimes9d
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
"MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an unmet ...